🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Rilvegostomig

Also listed in trial records as AZD8205 and AZD2936, AZD8205 and AZD5305 (saruparib) and AZD2936, AZD2936
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 29 trials in our USA, China, UK, India and Ireland registers that name Rilvegostomig as an intervention. Synced 24 Sep 2026
29Trials tracked
21Recruiting now
2Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards

Rilvegostomig is named as a drug or biological intervention in 29 clinical trials in our USA, China, UK, India and Ireland trial registers, 21 of which are recruiting. Lead sponsors include AstraZeneca (28) and Presage Biosciences (1). Registered phases: Phase 3, Phase 2, Phase 1/2, Phase 1 and Phase EARLY_PHASE1. Conditions studied include Non-small Cell Lung Cancer; Gastric Cancer; Biliary Tract Cancer.

01

Clinical trials of Rilvegostomig

29 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06357533 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT06467357 Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer (ClinicalTrials.gov ↗)
Biliary Tract Cancer
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT06627647 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC (ClinicalTrials.gov ↗)
Non-squamous Non-small Cell Lung Cancer
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT06692738 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT06764875 A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer (ClinicalTrials.gov ↗)
HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT06868277 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
 Phase 3 Recruiting AstraZeneca Ireland, UK, USA, China
NCT06921785 Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT06989112 DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (ClinicalTrials.gov ↗)
Endometrial Cancer
 Phase 3 Recruiting AstraZeneca UK, USA, China
NCT07221253 A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (ClinicalTrials.gov ↗)
Biliary Tract Cancer
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT07431281 Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 (ClinicalTrials.gov ↗)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT07720284 An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC (ClinicalTrials.gov ↗)
High-risk Muscle Invasive Urothelial Carcinoma
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT05061550 Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 2 Recruiting AstraZeneca Ireland, USA
NCT05489211 Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer
 Phase 2 Recruiting AstraZeneca UK, USA, China
NCT05702229 Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗)
Gastric Cancer
 Phase 2 Recruiting AstraZeneca UK, USA, China
NCT07069712 A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (ClinicalTrials.gov ↗)
Gastroesophageal Adenocarcinoma
 Phase 2 Recruiting AstraZeneca UK, USA, China
NCT07098338 A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 2 Recruiting AstraZeneca USA, China
NCT05123482 A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies (ClinicalTrials.gov ↗)
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer
 Phase 1/2 Recruiting AstraZeneca UK, USA, China
NCT06996782 A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Advanced or Metastatic Non-small Cell Lung Cancer
 Phase 1/2 Recruiting AstraZeneca USA, China
NCT07115043 A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗)
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)
 Phase 1/2 Recruiting AstraZeneca USA
NCT04686305 Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (ClinicalTrials.gov ↗)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
 Phase 1 Recruiting AstraZeneca USA, China
NCT07161414 A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ClinicalTrials.gov ↗)
Advanced Solid Tumors
 Phase 1 Recruiting AstraZeneca UK, USA
NCT04541108 Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (ClinicalTrials.gov ↗)
Solid Tumor
 Phase EARLY_PHASE1 Active, closed Presage Biosciences USA
NCT06109779 Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (ClinicalTrials.gov ↗)
Biliary Tract Cancer
 Phase 3 Active, closed AstraZeneca UK, USA, India, China
NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 3 Active, closed AstraZeneca USA
NCT04379596 Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (ClinicalTrials.gov ↗)
Gastric Cancer
 Phase 2 Active, closed AstraZeneca UK, USA, China
NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (ClinicalTrials.gov ↗)
Hepatocellular Carcinoma, Biliary Tract Cancer
 Phase 2 Active, closed AstraZeneca UK, USA, China
NCT04995523 A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Non-Small-Cell Lung Carcinoma
 Phase 1/2 Active, closed AstraZeneca USA, China
NCT03819465 A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Metastatic Non-Small Cell Lung Cancer (NSCLC)
 Phase 1 Active, closed AstraZeneca USA
NCT04612751 Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Advanced or Metastatic NSCLC
 Phase 1 Active, closed AstraZeneca USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

27 conditions
Condition (as registered)Trials
Non-small Cell Lung Cancer4
Gastric Cancer4
Biliary Tract Cancer4
Endometrial Cancer3
Hepatocellular Carcinoma2
Ovarian Cancer2
Non-Small Cell Lung Cancer2
Gastroesophageal Junction Adenocarcinoma2
Carcinoma, Non-Small Cell Lung1
Metastatic Castration-resistant Prostate Cancer1
Breast Cancer1
Biliary Tract Carcinoma1
Advanced Solid Tumors1
Non-squamous Non-small Cell Lung Cancer1
High-risk Muscle Invasive Urothelial Carcinoma1
HER2-positive Gastric Cancer1
Esophageal Cancer1
Gastroesophageal Adenocarcinoma1
Advanced or Metastatic Non-small Cell Lung Cancer1
Solid Tumor1
Melanoma1
Squamous Cell Carcinoma (Skin)1
Renal Cell Carcinoma1
Locally Advanced or Metastatic Non-Small Cell Lung Cancer1
Metastatic Non-Small Cell Lung Cancer (NSCLC)1
Non-Small-Cell Lung Carcinoma1
Advanced or Metastatic NSCLC1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
AstraZeneca28
Presage Biosciences1
04

Trials by country register

RegisterRilvegostomig trials
Clinical trials in USA29
Clinical trials in China22
Clinical trials in UK19
Clinical trials in India10
Clinical trials in Ireland2

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rilvegostomig works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rilvegostomig (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.